Search results for " LDL cholesterol"

showing 5 items of 5 documents

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

2018

Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available suppleme…

ConsensusFunctional foodsClinical Decision-MakingFood supplementDisease030204 cardiovascular system & hematologyLDL03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalPlasma cholesterolRisk FactorsEnvironmental healthFood supplementsRed yeast riceMedicineAnimalsHumans030212 general & internal medicineCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Clinical Decision-Making; Consensus; Dyslipidemias; Evidence-Based Medicine; Humans; Protective Factors; Risk Factors; Diet Healthy; Dietary Supplements; Functional Food; Risk Reduction BehaviorDyslipidemiasPharmacologyLdl cholesterolHealthyEvidence-Based MedicinePrimary preventionCholesterolbusiness.industryFunctional foodFood supplementation functional foods cholesterol LDL-cholesterol cardiovascular risk primary preventionCholesterol LDLProtective FactorsCardiovascular riskDietCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; PharmacologyYoung ageCholesterolchemistryCardiovascular DiseasesDietary SupplementsLDL cholesterolPosition paperDiet HealthybusinessRisk Reduction BehaviorBiomarkers
researchProduct

Familial hypercholesterolæmia in children and adolescents: Gaining decades of life by optimizing detection and treatment

2015

Contains fulltext : 155263.pdf (Publisher’s version ) (Open Access) Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on phenotypic criteria, i.e. an elevated low-density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, premature coronary artery disease and/or genetic diagnosis, or positive genetic testin…

CounselingEuropean Atherosclerosis Society Consensus PanelPediatricsCardiac & Cardiovascular SystemsSTATIN THERAPYSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Familial hypercholesterolemiaAdolescentsCarotid Intima-Media ThicknessINTIMA-MEDIA THICKNESSCost of IllnessPregnancyRisk FactorsDiagnosisYOUNG-ADULTSHIPERCOLESTEROLEMIA (DIAGNÓSTICO;TERAPIA;TENDÊNCIAS)Family historyYoung adultChildChildrenEvidence-Based Medicinemedicine.diagnostic_testHomozygoteMiddle AgedFamilial hypercholesterolæmia3. Good healthEconomics MedicalAdolescents; Children; Consensus statement; Diagnosis; Ezetimibe; Familial hypercholesterolæmia; LDL cholesterol; PCSK9 inhibitor; Statin; Treatment; Cardiology and Cardiovascular MedicineCARDIOVASCULAR-DISEASEConsensus statementLDL cholesterolFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & BiomedicineDiagnosimedicine.drugAdultHeterozygotemedicine.medical_specialtyStatinAdolescentmedicine.drug_classPCSK9 inhibitorENDOTHELIAL FUNCTIONLOW-DENSITY-LIPOPROTEINReviewsCOST-EFFECTIVENESS ANALYSIS1102 Cardiovascular Medicine And HaematologyMedication AdherenceHyperlipoproteinemia Type IIYoung AdultLife ExpectancyEzetimibemedicineHumansCORONARY-HEART-DISEASEGenetic TestingGenetic testingPregnancyScience & TechnologyClinical Laboratory Techniquesbusiness.industryPreventionStatinAtherosclerosismedicine.diseaseEzetimibeDietASSOCIATION EXPERT PANELBLOOD-PRESSURE RESEARCHPregnancy ComplicationsTreatmentEarly DiagnosisIntima-media thicknessCardiovascular System & HematologyDietary SupplementsPhysical therapyCardiovascular System & Cardiologybusiness
researchProduct

National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio : a pooled analy…

2020

Artículo con numerosos autores. Sólo quedan reflejados el primero, los pertenecientes a la UAM y el colectivo

Malegupo de ascendencia continental asiáticaSettore MED/09 - Medicina InternaTotal Cholesterol ; Ldl Cholesterol ; Hdl Cholesterol ; Blood Lipids ; Multi-country StudyEpidemiologykolesterolihumanosBlood lipidsBLOOD-PRESSURE030204 cardiovascular system & hematologytriglicéridoschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinHDL cholesterolEpidemiologyMedicine and Health SciencesCARDIOVASCULAR RISK-FACTORSMedicine030212 general & internal medicinemediana edadlípidosPublic Environmental & Occupational Health2. Zero hungerancianoeducation.field_of_studyAge FactorsPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineMiddle Agedcolesteroladultokansainvälinen vertailuLipids3142 Public health care science environmental and occupational health3. Good healthEuropeCholesterolPopulation SurveillanceLDL cholesterolSERUM-LIPIDSFemalelipids (amino acids peptides and proteins)Life Sciences & BiomedicineAdultAsian Continental Ancestry GroupCanadaHDL cholesterol; LDL cholesterol; Total cholesterol; blood lipids; multi-country studymedicine.medical_specialtyAsiaMedicinaEuropean Continental Ancestry GroupPopulationNursingHDL-kolesteroliWhite PeopleDIETARY-FAT03 medical and health sciencesSex FactorsAsian Peoplekansanterveysvigilancia de la poblaciónTotal cholesterolHumansCORONARY-HEART-DISEASEmulti-country studyddc:610LDL-kolesteroliTotal cholesteroleducationTriglyceridesMETAANALYSISAgedINDIVIDUAL DATAScience & Technologyblood lipidsbusiness.industryCholesterolOmvårdnadblood lipidCholesterol HDLEcological studynutritional and metabolic diseasesCholesterol LDLUnited StatesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiAdult; Age Factors; Aged; Asia; Asian Continental Ancestry Group; Canada; Cholesterol/blood; Cholesterol HDL; Cholesterol LDL; Europe; European Continental Ancestry Group; Female; Humans; Lipids/blood; Male; Middle Aged; Population Surveillance/methods; Sex Factors; Triglycerides/blood; United States; HDL cholesterol; LDL cholesterol; Total cholesterol; blood lipids; multi-country studychemistryWORLDWIDE TRENDSMulti-country study ; Total cholesterol ; HDL cholesterol ; LDL cholesterol ; Blood lipidsgrupo de ascendencia continental europeabusinessHIGH-DENSITY-LIPOPROTEIN[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemographyLipoprotein
researchProduct

Mipomersen: a lipid-lowering agent with a novel mechanism of action

2013

“...mipomersen is a ... valuable alternative to apheresis for patients with heterozygous familial hypercholesterolemia.”

inorganic chemicalsLdl cholesterolChemistryEndocrinology Diabetes and MetabolismMipomersenLipid-lowering agentnutritional and metabolic diseasesPharmacologybehavioral disciplines and activitieshumanitiesantisense oligonucleotides LDL cholesterol lipid lowering mipomersen statinsApheresisMechanism of actionAntisense oligonucleotidesmedicineLipid loweringmedicine.symptomCardiology and Cardiovascular Medicinehealth care economics and organizationsClinical Lipidology
researchProduct